Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-003 in platinum-resistant/refractory ovarian cancer
NCT02539719Phase 1Terminated
- Sponsor
- Stemcentrx
- Start
- Aug 2015
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of Tamrintamab pamozirine in ovarian cancer, sponsored by Stemcentrx. Started Aug 2015; status: terminated.
02
Drugs
Tamrintamab pamozirine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02539719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02539719.